Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Opaleye Management portfolio

Concentrated managerInvestment firm
Follow Opaleye Management
Share

Portfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Opaleye Management reported a $1.1 bn portfolio of 58 positions to the SEC as of the end of Q2 2026. Its largest positions are LQDA, ETON, HROW. During the quarter it opened Immix Biopharma and Monte Rosa Therapeutics and exited Perspective Therapeutics.

Stock portfolio
$1.1 bn
Positions
58
Top 10: 65%
Turnover
23%
Copying its 13F, 5 years
—
No 5 straight years measured as a concentrated manager

Sections with a free account

What it reported after the quarter end (Q2 2026)

The 13F shows the portfolio as of Jun 30, 2026. Since then Opaleye Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.

Plus 3 more, in its EDGAR filings.

What changed this quarter

42 positions with a change (11 new, 12 added to, 12 trimmed, 7 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).

The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.

Top holdings

“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.

Portfolio by sector

  • ● Health Care 99%
  • ● Materials 1%

How its portfolio changed (8 quarters)

Positions

Q2 2026: 58

580
Q3 2024Q2 2026
Top 10 weight

Q2 2026: 65%

78%62%
Q3 2024Q2 2026
Traded turnover

Q2 2026: 11.2%

21.6%0
Q3 2024Q2 2026

Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.

13F filings with amendments or confidential positions

Stakes above 5% (13D/13G)

Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.

How we classify it

Investment firm, per its Form ADV of Feb 19, 2026 (high confidence).

The data, as reported: OPALEYE MANAGEMENT INC. (CRD 124513): 7.B private funds: 1 hedge (gross assets $789M); 5.D assets by client type: pooled vehicles 98% (of $803M)

The type comes from a rule applied to that data. If it looks wrong, tell us.

Similar managers by type and size

Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.

Follow Opaleye Management for free

When the next 13F is filed, we email you (if you turn it on) and it shows in your list. No credit card.

Follow Opaleye Management